



# LAS VEGAS PSYCH SERVICES

2341 Renaissance Drive, Ste A  
Las Vegas, NV 89119  
Tel. (702) 405-9080 · Fax (702) 405-9240  
Email. [reception@tgxlv.com](mailto:reception@tgxlv.com)

December 6, 2021

Pharmacy and Therapeutics Committee  
State of Nevada Department of Health and Human Services  
Division of Health Care Financing and Policy  
1100 E. William Street, Suite 101  
Carson City, NV 89701

Re: Agenda Item 5.f, Discussion, and possible adoption of psychotropic agents- antipsychotics- atypical antipsychotics, oral

To whom it may concern,

I am writing this letter in regards to the review of oral atypical antipsychotics for the preferred drug list that will be held by Nevada Medicaid at their therapeutics committee meeting on December 9, 2021. I would highly recommend that Caplyta (lumateperone) be added to the preferred drug list.

This recommendation is based on the efficacy that I have observed on many of my patients diagnosed with schizophrenia that have been started on this medication. Due to no titration or 'starting dose', this is a medication that is not complicated for patients to start on, and to continue taking as a once-a-day capsule. There is an increase in adherence to their treatment plan when compared to the other medications. I have tried other atypical antipsychotics, but patients have failed to feel improvement of their symptoms as fast as they do with Caplyta. It has also been well received amongst my patients since they do not feel as many metabolic side effects as they experienced previously with other atypical antipsychotics.

Adding this medication on the preferred drug list will expand patient's choices in order to help them find a medication that will properly stabilize their condition. Thank you for your consideration.

I am licensed by the state of Nevada to practice clinical psychiatry. My license number is LIC#12178.

Thank you

Paul Nguyen, M.D.